Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.
Iovance Biotherapeutics is facing a three-month delay in the review of its lifileucel cell therapy for melanoma in the US, held up by "insufficient resources" at the FDA.<
Iovance Biotherapeutics could be a few months away from a first regulatory approval for lifileucel, which could be the first cell-based therapy for a solid tumour in the U
A $650 million programme set up by pharma group MSD to help prevent maternal mortality and improve health equity around the world has reached over 30 million women, easily
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.